These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17938193)

  • 1. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
    Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
    Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
    Alvirez-Freites EJ; Carter JL; Cynamon MH
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1022-5. PubMed ID: 11897584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
    Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
    Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
    Homma T; Hori T; Sugimori G; Yamano Y
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
    Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2008 Jan; 12(1):69-73. PubMed ID: 18173880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
    Willby M; Sikes RD; Malik S; Metchock B; Posey JE
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5427-34. PubMed ID: 26100699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.
    Sebastian J; Swaminath S; Nair RR; Jakkala K; Pradhan A; Ajitkumar P
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
    Ji B; Lounis N; Maslo C; Truffot-Pernot C; Bonnafous P; Grosset J
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2066-9. PubMed ID: 9687408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.
    Ginsburg AS; Sun R; Calamita H; Scott CP; Bishai WR; Grosset JH
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3977-9. PubMed ID: 16127087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
    Allen GP; Hankins CD
    J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.
    Croisier D; Etienne M; Bergoin E; Charles PE; Lequeu C; Piroth L; Portier H; Chavanet P
    Antimicrob Agents Chemother; 2004 May; 48(5):1699-707. PubMed ID: 15105123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense.
    Choi GE; Min KN; Won CJ; Jeon K; Shin SJ; Koh WJ
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3549-55. PubMed ID: 22564831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
    Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.